Jeffrey Conrad Laurence, M.D.
< Back to Search Results

Jeffrey Conrad Laurence, M.D.


Profile Photo of Jeffrey Conrad Laurence, M.D.
Accepts New Patients
Gender: Male
Language: English


Personal Statement

Our medical center provides an extraordinary opportunity to work with clinicians and scientists with expertise in all facets of HIV/AIDS and clotting disorders associated with small blood vessel injury such as TTP and aHUS. Working with them in the diagnosis and treatment of these diseases for over 25 years, I have developed a strong interest in HIV-related hematologic disorders as well as osteoporosis and other metabolic complications arising during antiretroviral therapy for HIV.

Specialties and Expertise


  • Medical Oncology
  • Hematology


  • Thrombotic Microangiopathy
  • Hypercoagulable State
  • HIV-Related Blood Disorders


Dr. Laurence is Professor of Medicine in the Division of Hematology-Oncology, Attending Physician at New York Presbyterian Hospital, and Director of the Laboratory for AIDS Virus Research at those institutions. He is also Senior Scientific Consultant for Programs at amfAR, The Foundation for AIDS Research, and Editor-in-Chief of two medical journals: AIDS Patient Care and STDs (in its 24th year), and Translational Research (formerly the Journal of Laboratory and Clinical Medicine, in its 96th year).

Dr. Laurence received his B.A. Phi Beta Kappa, summa cum laude from Columbia University in 1972, and his M.D. with honors from the University of Chicago Pritzker School of Medicine in 1976. He was elected a Rhodes Scholar to Oxford University in 1973. Deferring this honor, he accepted a Henry Luce Fellowship to Japan, where he worked as a research associate at the Institute for Cancer Research in Osaka from 1974-1975. Dr. Laurence returned to New York to complete a residency in internal medicine, followed by fellowships in hematology and oncology at The New York Hospital.

In 1983 Dr. Laurence was invited to the Institut Pasteur in Paris to collaborate with Drs. Luc Montagnier and Francoise Barre-Sinoussi, recent Nobel laureates for the discovery of HIV. Dr. Laurence was first author on their 1984 paper in the New England Journal of Medicine further documenting LAV/HIV as the cause of AIDS, and identifying a carrier state for HIV infection. His current work focuses on the mechanisms by which HIV affects endothelial cells and osteoclasts, in models for microvascular thrombosis and osteoporosis linked to HIV infection and its treatment. He also has a long-standing interest in clotting disorders associated with microvessel injury, including TTP and aHUS. Dr. Laurence is also involved in a gene therapy project, by which anti-HIV anti-sense genes are inserted into the stem cells of advanced AIDS patients who are recalcitrant to drug therapy. This is followed by bone marrow ablation and re-infusion of those HIV resistant stem cells back into the patients.

Dr. Laurence has authored over 150 scientific papers related to AIDS. He is a member of several private national and international AIDS organizations. He is a recipient of the Clinician-Scientist Award of the American Heart Association and the William S. Paley Fellowship in Academic Medicine, is a member of the National Council of The Jackson Laboratory, and is an elected Fellow of the New York Academy of Sciences and member of the American Society for Clinical Investigation. He has 3 children--Auden, Galen and Luca--and lives in Greenwich, CT.


Honors and Awards

Honors and Awards

American Society for Clinical Investigation

Fellow, New York Academy of Sciences

Clinician-Scientist Award, American Heart Association

William S. Paley Fellow in Academic Medicine

Henry Luce Foundation Scholar (to Institute for Cancer Research, Osaka, Japan)

Rhodes Scholar elect


Board Certifications

  • American Board of Internal Medicine

Clinical and Academic Positions

  • Professor of Medicine - Weill Cornell Medical College, Cornell University
  • Attending Physician - NewYork-Presbyterian Hospital

Education and Training

  • M.D., University of Chicago Pritzker School of Medicine, 1976


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this doctor. If your insurance carrier does not appear here please contact the doctor’s office as they may have individual contracts not included on this site.

* indicates this doctor is no longer accepting new patients with this insurance plan.

  • AETNA - Medicare
  • Aetna Weill Cornell Employee Managed Care Plan
  • Aetna Weill Cornell Employee PPO Plan
  • Aetna-NYP - EPO/POS
  • Affinity Access
  • Affinity Health Plan
  • AgeWell New York
  • Amida Care
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield - Blue Access
  • Empire Blue Cross/Blue Shield - Blue Connection
  • Empire Blue Cross/Blue Shield - EPO
  • Empire Blue Cross/Blue Shield - HMO
  • Empire Blue Cross/Blue Shield - Mediblue (Senior)
  • Empire Blue Cross/Blue Shield - PPO
  • Empire Blue Cross/Blue Shield HealthPlus
  • Empire Blue Cross/Blue Shield HealthPlus - CHP
  • Fidelis Care
  • GHI - CBP
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) - Medicaid
  • Health Insurance Plan of NY (HIP) - Medicare
  • Medicaid
  • Medicare
  • Oxford Health Plans - Freedom
  • Oxford Health Plans - Liberty
  • Oxford Health Plans - Medicare Advantage
  • Oxford Health Plans - Metro/Core/Charter
  • Rockefeller University - Trustmark
  • United Empire
  • United Healthcare
  • United Healthcare - Community Plan
  • United Healthcare - Medicare
  • United Healthcare Compass
  • VNSNY CHOICE - Medicare
  • WellCare of NY
  • WorldWide Medical

Locations and Appointments

External Relationships

External Relationships

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Jazz Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.; Omeros Corporation